A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)

Toshiaki Shibasaki,Akio Koyama,Akira Hishida,Eri Muso,Gengo Osawa,Hideaki Yamabe,Hideo Shiiki,Hirofumi Makino,Hiroshi Sato,Isao Ishikawa,Kenji Maeda,Kimio Tomita,Masaaki Arakawa,Masashi Ishida,Masashi Sato,Mitsumasa Nagase,Naoki Kashihara,Noriaki Yorioka,Takao Koike,Takao Saito,Takashi Harada,Tetsuya Mitarai,Tetsuzo Sugisaki,Toshihiko Nagasawa,Yasuhiko Tomino,Yoshihisa Nojima,Yutaka Kobayashi,Osamu Sakai

A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)

2004

Background A previous double-blind 24-week clinical trial of mizoribine (MZ) vs placebo in steroid-resistant primary nephrotic syndrome (SRPNS) showed that MZ was more effective than placebo in reducing the rate of deterioration of renal function. The present study was conducted to evaluate the efficacy and safety of MZ in patients with SRPNS after 2 years’ treatment.

Keywords:

Steroid-resistant nephrotic syndrome
Endocrinology
Randomized controlled trial
Mizoribine
Internal medicine
Clinical trial
Nephrotic syndrome
Membranous nephropathy
Placebo
Adverse effect
Medicine
Renal function
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations